

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “**Meeting**”) of China NT Pharma Group Company Limited (the “**Company**”) will be held on Friday, 28 August 2026, 11 a.m. at Unit 2102, 21/F, West Tower, Shun Tak Centre, 168–200 Connaught Road Central, Hong Kong for the purpose of considering and, if thought fit, passing with or without amendments, the following resolutions of the Company:

ORDINARY RESOLUTIONS

1. “**THAT**, subject to the fulfilment of the terms and conditions set out in (i) the subscription agreement dated 17 June 2026 (the “**First Subscription Agreement**”, copy of which has been produced to this meeting marked “A” and initialed by the Chairman for the purpose of identification) entered into between the Company and Golden Base Investment Limited, a company incorporated in the British Virgin Islands with limited liability (the “**First Subscriber**”), pursuant to which the Company has conditionally agreed to allot and issue to First Subscriber, and First Subscriber has conditionally agreed to subscribe for, 452,846,627 new Shares (the “**First Subscription Shares**”) at the Subscription Price of HK\$0.365 per Subscription Share for a total consideration of HK\$165,289,018.86, which shall be satisfied by way of offsetting the debt in the aggregate outstanding amount of HK\$165,289,018.90 owed by the Company to the First Subscriber as at 17 June 2026; (ii) the subscription agreement dated 17 June 2026 (the “**Second Subscription Agreement**”, copy of which has been produced to this meeting marked “B” and initialed by the Chairman for the purpose of identification) entered into between the Company and Annie Investment Co., Ltd, a company incorporated in the British Virgin Islands with limited liability (the “**Second Subscriber**”), pursuant to which the Company has conditionally agreed to allot and issue to Second Subscriber, and Second Subscriber has conditionally agreed to subscribe for, 250,849,772 new Shares (the “**Second Subscription Shares**”) at the Subscription Price of HK\$0.365 per Subscription Share for a total consideration of HK\$91,560,166.78, which shall be satisfied by way of offsetting the debt in the aggregate amount of HK\$91,560,166.91 owed by the Company to the Second Subscriber as at 17 June 2026; (iii) the subscription agreement dated 17 June 2026 (the “**Third Subscription Agreement**”, copy of which has been produced to this meeting marked “C” and initialed by the Chairman for the purpose of identification) entered into between the Company and Mr. Ng Andy Ching Kit, the son of Mr. Ng Tit (the “**Third Subscriber**”), pursuant to which the Company has conditionally agreed to allot and issue to Third Subscriber, and Third Subscriber has conditionally agreed to

subscribe for, 15,190,793 new Shares (the “**Third Subscription Shares**”) at the Subscription Price of HK\$0.365 per Subscription Share for a total consideration of HK\$5,544,639.45, which shall be satisfied by way of offsetting the debt in the aggregate amount of HK\$5,544,639.61 owed by the Company to the Third Subscriber as at the date of 17 June 2026; (iv) the subscription agreement dated 17 June 2026 (the “**Fourth Subscription Agreement**”, copy of which has been produced to this meeting marked “D” and initialed by the Chairman for the purpose of identification) entered into between the Company and Ms. Ng Anna Ching Mei (the “**Fourth Subscriber**”), an executive Director and the daughter of Mr. Ng Tit, pursuant to which the Company has conditionally agreed to allot and issue to Fourth Subscriber, and Fourth Subscriber has conditionally agreed to subscribe for, 48,418,483 new Shares (the “**Fourth Subscription Shares**”) at the Subscription Price of HK\$0.365 per Subscription Share for a total consideration of HK\$17,672,746.30, which shall be satisfied by way of offsetting the debt in the aggregate amount of HK\$17,672,746.46 owed by the Company to Fourth Subscriber as at the date of 17 June 2026; (v) the subscription agreement dated 17 June 2026 (the “**Fifth Subscription Agreement**”, copy of which has been produced to this meeting marked “E” and initialed by the Chairman for the purpose of identification) entered into between the Company and Ms. Ng Tit (the “**Fifth Subscriber**”), pursuant to which the Company has conditionally agreed to allot and issue to Fifth Subscriber and Fifth Subscriber has conditionally agreed to subscribe for, 4,750,009 new Shares (the “**Fifth Subscription Shares**”) at the Subscription Price of HK\$0.365 per Subscription Share for a total consideration of HK\$1,733,753.29, which shall be satisfied by way of offsetting the debt in the aggregate amount of HK\$1,733,753.42 owed by the Company to Fifth Subscriber as at the date of 17 June 2026; (vi) the subscription agreement dated 17 June 2026 (the “**Sixth Subscription Agreement**”, copy of which has been produced to this meeting marked “F” and initialed by the Chairman for the purpose of identification) entered into between the Company and Mr. Wong Kim Shan (the “**Sixth Subscriber**”), pursuant to which the Company has conditionally agreed to allot and issue to the Sixth Subscriber, and the Sixth Subscriber has conditionally agreed to subscribe for, 41,095,890 new Shares (the “**Sixth Subscription Shares**”) at the Subscription Price of HK\$0.365 per Subscription Share for a total consideration of HK\$14,999,999.85, which shall be satisfied by way of offsetting the debt in the aggregate amount of HK\$15,000,000 owed by the Company to Sixth Subscriber as at the date of 17 June 2026; (vii) the subscription agreement dated 17 June 2026 (the “**Seventh Subscription Agreement**”, copy of which has been produced to this meeting marked “G” and initialed by the Chairman for the purpose of identification, together with First Subscription Agreement, Second Subscription Agreement, Third Subscription Agreement, Fourth Subscription Agreement, Fifth Subscription Agreement and Sixth Subscription Agreement, the “**Subscription Agreements**”) entered into between the Company and Hangzhou Aisi Life Technology Co., Ltd. (the “**Seventh Subscriber**”, together with First Subscriber, Second Subscriber, Third Subscriber, Fourth Subscriber, Fifth Subscriber and Sixth Subscriber, the “**Subscribers**”), pursuant to which the Company has conditionally agreed to allot and issue to the Seventh Subscriber, and the Seventh Subscriber has conditionally agreed

to subscribe for, 34,414,318 new Shares (the “**Seventh Subscription Shares**”, together with First Subscription Shares, Second Subscription Shares, Third Subscription Shares, Fourth Subscription Shares, Fifth Subscription Shares and Sixth Subscription Shares, the “**Subscription Shares**”) at the Subscription Price of HK\$0.365 per Subscription Share for a total consideration of HK\$12,561,226.07, which shall be satisfied by way of offsetting the debt in the aggregate amount of HK\$12,561,226.03 owed by the Company to the Seventh Subscriber as at the date of 17 June 2026:

- (a) the Subscription Agreements and the matters contemplated thereunder be and are hereby approved, confirmed and ratified;
 - (b) all the transactions contemplated under the Subscription Agreements, including but not limited to the specific mandate to allot and issue the Subscription Shares by the Company to the Subscribers pursuant to the Subscription Agreements, be and are hereby approved and the Directors be and are hereby authorised to allot and issue the Subscription Shares to the Subscribers pursuant to the Subscription Agreements; and
 - (c) any one or more of the Directors be and is/are hereby authorised to do all such acts and things and execute all such documents which he/she/they consider necessary, desirable or expedient for the purpose of, or in connection with the implementation of and giving effect to the Subscription Agreements and the transactions contemplated thereunder.”
2. “**THAT** CCTH CPA Limited be and is hereby appointed as the auditor of the Company to fill the casual vacancy following the retirement of Moore CPA Limited, with effect from the passing of this resolution, to hold office until the conclusion of the next annual general meeting of the Company, and that the board of directors of the Company be and is hereby authorised to fix their remuneration.”

Yours faithfully,
For and on behalf of
China NT Pharma Group Company Limited
Ng Tit
Chairman of the Board

Hong Kong, 10 August 2026

Notes:

1. A member entitled to attend and vote at the Meeting is entitled to appoint one or more proxy to attend and, subject to the provisions of the articles of association of the Company, to vote on his/her/its behalf. A proxy need not be a member of the Company but must be present in person at the Meeting to represent the member. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.

2. A form of proxy for use at the Meeting is enclosed. Whether or not you intend to attend the Meeting in person, you are encouraged to complete and return the enclosed form of proxy in accordance with the instructions printed thereon. Completion and return of a form of proxy will not preclude a member from attending in person and voting at the Meeting or any adjournment thereof, should he/she/it so wish.
3. In order to be valid, the form of proxy, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 48 hours before the time appointed for holding the Meeting or any adjournment thereof.
4. The register of members of the Company will be closed from 25 August 2026 to 28 August 2026 (both days inclusive), during which period no transfer of shares will be effected. In order to qualify for the entitlement to attend and vote at the above meeting, all transfer forms accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on 24 August 2026 for registration.
5. If typhoon signal No. 8 or above, or a "black" rainstorm warning is in effect any time after 7:00 a.m. on the date of the Meeting, the meeting will be postponed. The Company will publish a circular on the website of the Company at <https://www.ntpharma.com> and on the Stock Exchange website at <http://www.hkexnews.com> to notify shareholders of the Company of the date, time and place of the rescheduled meeting.
6. As at the date hereof, the Board comprised:

Executive Directors:

Mr. Ng Tit (*Chairman*)
Ms. Ng Anna Ching Mei

Non-executive Directors:

Dr. Qian Wei
Ms. Chin Yu
Mr. Lou Yongbin

Independent non-executive Directors:

Mr. Yu Tze Shan Hailson
Mr. Kwok Che Chung
Dr. Zhao Yubiao